GSK leukemia treatment Arzerra filed for regulatory approval in Japan

Chronic lymphoctyic leukemia Leukemia treatment Arzerra, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Genmab (CSE:GEN), has been submitted for approval in Japan. Arzerra has currently rece…
Read the full story: MedCity News